Phase 1 Study of E7090 in Subjects With Solid Tumor
Status:
Completed
Trial end date:
2021-09-03
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study of E7090 in subjects with advanced solid tumors. This study will be
conducted in 2 parts:
1. Part 1 will be the dose escalation portion of this study to determine the maximum
tolerated dose in subjects with solid tumors, and
2. Part 2 will comprise cohort expansions to further characterize the safety and
tolerability of E7090 and to assess preliminary efficacy of E7090 in subjects with solid
tumors characterized by genetic abnormalities in FGF/FGFR pathway.